NCT06258291View on ClinicalTrials.gov

First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression

NANot yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

July 28, 2026

Study Completion Date

December 30, 2026

Conditions
Septic Shock
Interventions
DEVICE

Hemosystem REBOOT

The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.

Trial Locations (2)

Unknown

University Hospital Bern Inselspital, Bern

University Hospital Zurich, Zurich

All Listed Sponsors
lead

hemotune AG

INDUSTRY

NCT06258291 - First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression | Biotech Hunter | Biotech Hunter